Back to News
research

Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Fulcrum Therapeutics held its Q1 2026 earnings call on April 27, led by CEO Alex Sapir, CFO Alan Musso, and SVP Iain Fraser, detailing financial results and clinical progress. The company emphasized forward-looking statements about clinical timelines and financial projections, warning investors of potential risks per SEC filings. Key updates included pipeline advancements, though specific program details were not disclosed in the transcript excerpt. Analysts from firms like JPMorgan, Goldman Sachs, and Leerink Partners participated in the Q&A, signaling strong institutional interest. The call was recorded and webcast live on Fulcrum’s investor website, with no obligation to update future statements.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (19).png
Quantum News · Media Library

SA Transcripts159.46K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call April 27, 2026 8:00 AM EDT Company Participants Alexander Sapir - CEO, President & DirectorAlan Musso - Chief Financial OfficerIain Fraser - Senior Vice President of Early Development Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research DivisionAnupam Rama - JPMorgan Chase & Co, Research DivisionKristen Kluska - Cantor Fitzgerald & Co., Research DivisionCorinne Jenkins - Goldman Sachs Group, Inc., Research DivisionJames Condulis - Stifel, Nicolaus & Company, Incorporated, Research DivisionMatthew Biegler - Oppenheimer & Co. Inc., Research DivisionGregory Renza - Truist Securities, Inc., Research Division Presentation Operator Good morning, and welcome to Fulcrum Therapeutics First Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, may include statements about the company's future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent Fulcrum's views as of today, they should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; and Dr. Iain Fraser, Senior Vice President, Clinical Development. After providing updates on the company's key programs, there will be a brief Q&A in which the Fulcrum management team will be available for questions.

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.